西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性

王世广 司旭艳 李晓婷 李登云 王丽君 王鹏*

doi:10.16098/j.issn.0529-1356.2019.06.009

PDF(397 KB)

解剖学报 ›› 2019, Vol. 50 ›› Issue (6) : 754-760. DOI: 10.16098/j.issn.0529-1356.2019.06.009

肿瘤生物学

西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性

王世广¹司旭艳²李晓婷¹ 李登云¹王丽君¹ 王鹏^3*

作者信息 +

Enhancing effect of chidamide on the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin

WANG Shi-guang¹ SI Xu-yan² LI Xiao-ting¹ LI Deng-yun¹ WANG Li-jun¹ WANG Peng^3*

Author information +

文章历史 +

摘要

目的观察西达本胺（CDM）能否影响人慢性髓系白血病耐药株K562/ADM细胞对柔红霉素（DNR）的敏感性，并探讨其可能的分子机制。方法体外常规培养K562细胞和K562/ADM细胞，给予不同剂量CDM和（或）DNR处理48 h后，采用细胞计数试剂盒8（CCK-8）法检测CDM与DNR对K562和K562/ADM细胞的毒性作用，采用Chou-Talalay中效分析法对两药的联合效应进行评价，采用流式细胞术检测细胞增殖、细胞周期和凋亡，采用Western blotting方法检测组蛋白2AX（H2AX）、γH2AX（Ser139）、共济失调毛细血管扩张征突变基因（ATM）、p-ATM（Ser1981）、乳腺癌易感蛋白l（BRCA1）和p-BRCA1（Ser1524）的蛋白表达水平。结果 DNR可剂量依赖性地抑制K562/ADM细胞活力（P<0.05），半数抑制浓度（IC50）为11.76 μmol/L，耐药倍数为18.09；CDM可协同增强DNR对K562/ADM细胞的抑制作用置信区间（CI）（CI<1），反转倍数为8.11；与对照组相比，DNR组细胞增殖率显著降低（P<0.05），G2/M期细胞比例和凋亡率明显升高（P<0.05），而无毒剂量的CDM可协同增强DNR引起的细胞增殖抑制、G2/M期阻滞和细胞凋亡（P<0.05）；耐药株K562/ADM细胞中ATM和BRCA1蛋白表达水平显著高于其亲代K562细胞（P<0.05）；DNR可上调K562/ADM细胞中H2AX、ATM和BRCA1蛋白的磷酸化水平（P<0.05）；CDM与DNR联用可使γH2AX蛋白水平进一步升高，但p-ATM和pBRCA1蛋白水平的变化则相反（P<0.05）。结论 CMD可反转K562/ADM细胞对DNR的耐药性，这可能与上调H2AX蛋白的磷酸化水平以及下调ATM和BRCA1蛋白的磷酸化水平有关。

Abstract

Objective To investigate whether chidamide (CDM) could influence the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin (DNR) and its possible mechanism. Methods The K562 and K562/ADM cells were cultured in vitro and treated with CDM and(or) DNR for 48 hous, and then the cell viability was measured by cell counting kit-8(CCK-8) assay. The proliferation, cell cycle and apoptosis were analyzed by flow cytometry. Western blotting was performed to measure the protein levels of histon 2AX(H2AX), γH2AX (Ser139), ataxia telangiectasia mutated gene (ATM), p-ATM (Ser1981), breast cancer susceptibility protein 1(BRCA1), and p-BRCA1 (Ser1524). Results DNR remarkably inhibited the cell activity of K562/ADM cells in dose-dependent manner with a half maximal inhibitory concentration(IC50) value of 11.76 μmol/L, and the resistant factor was 18.09. Co-treatment with CMD and DNR produced a synergistic effect confidence interval(Cl)(CI<1) with a reversal fold of 8.11. DNR remarkably inhibited proliferation (P<0.05), induced G2/M phase arrest and apoptosis (P<0.05), these effects were enhanced under non-toxic concentration of CMD (P<0.05). K562/ADM cells had a significantly higher protein levels of ATM and BRCA1 than K562 cells (P<0.05). DNR significantly up-regulated the protein levels of γH2AX, p-ATM and p-BRCA1 (P<0.05), and the protein level of γH2AX appeared higher in the combination group compared to DNR alone (P<0.05); however, the co-treatment with CMD and DNR induced a decreased expression of p-ATM and pBRCA1 than the DNR alone (P<0.05). Conclusion CDM may enhance the sensibility of K562/ADM cells to DNR by up-regulating the protein level of γH2AX, and down-regulating the protein levels of p-ATM and p-BRCA1.

导出引用

王世广司旭艳李晓婷李登云王丽君王鹏. 西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性[J]. 解剖学报. 2019, 50(6): 754-760 https://doi.org/10.16098/j.issn.0529-1356.2019.06.009

WANG Shi-guang SI Xu-yan LI Xiao-ting LI Deng-yun WANG Li-jun WANG Peng. Enhancing effect of chidamide on the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin[J]. Acta Anatomica Sinica. 2019, 50(6): 754-760 https://doi.org/10.16098/j.issn.0529-1356.2019.06.009

参考文献

［1］ Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid Leukemia in 2015［J］. Mayo Clin Proc, 2015, 90(10):1440-1454.

［2］ Perrone S, Massaro F, Alimena G, et al. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety［J］. Expert Opin Pharmacother, 2016, 17(11):1517-1526.

［3］ Lu X, Ning Z, Li Z, et al. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China［J］. Intractable Rare Dis Res, 2016, 5(3):185-191.

［4］ Simó-Riudalbas L, Esteller M. Targeting the histone orthography of cancer: drugs for writers, erasers and readers［J］. Br J Pharmacol, 2015, 172(11):2716-2732.

［5］ Li Y, Wang Y, Zhou Y, et al. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells［J］. Clin Epigenetics, 2017, 9(2017):83.

［6］ Shi P, Zhang L, Chen K, et al. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage［J］. Pharmacogenomics, 2017, 18(13):1259-1270.

［7］ He M, Qiao Z, Wang Y, et al. Chidamide inhibits aerobic metabolism to Induce pancreatic cancer cell growth arrest by promoting Mcl-1 degradation［J］. PLoS One, 2016, 11(11): e0166896.

［8］ Shi JY, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma［J］. Ann Oncol, 2015, 26(8):1766-1771.

［9］ Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin［J］. Nat Commun, 2013, 4:190

［10］ Cheng X,Jobin-Robitaille O,Billon P, et al. Phospho-dependent recruitment of the yeast NuA4 acetyltransferase complex by MRX at DNA breaks regulates RPA dynamics during resection［J］. Proc Natl Acad Sci USA, 2018, 115(40):10028-10033.

［11］ Ackermann L,Schell M,Pokrzywa W, et al. E4 ligase-specific ubiquitination hubs coordinate DNA double-strand-break repair and apoptosis［J］. Nat Struct Mol Biol, 2016, 23(11):995-1002.

［12］ Wagner W,Ciszewski WM,Kania KD. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation［J］. Cell Commun Signal, 2015, 13:36.

［13］ Blackford AN,Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response［J］. Mol Cell, 2017, 66(6):801-817.

［14］ Xing XK, Li MH, Xu CSh, et al. Expression changes of AKT，ATM，D4-GDI and p53 cell apoptosis pathway genes in the process of rat liver regeneration［J］. Acta Anatomica Sinica, 2016, 47(3):315-322. (in Chinese)

邢雪琨, 李梦华, 徐存拴, 等. AKT、ATM、D4-GDI 和p53 4 条细胞凋亡通路基因在大鼠肝再生过程中的表达变化［J］. 解剖学报, 2016, 47(3):315-322.

［15］ Isono M,Niimi A, Oike T, et al. BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation［J］. Cell Rep, 2017, 18(2):520-532.

［16］ Badie S, Carlos AR, Folio C, et al. BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres［J］. EMBO J, 2015, 34(3):410-424.

［17］ Siddiqui MS,Franois M,Fenech MF, et al. Persistent γH2AX: a promising molecular marker of DNA damage and aging［J］. Mutat Res Rev Mutat Res, 2015, 766(2015):1-19.

［18］ Timme CR, Rath BH, O’Neill JW, et al. The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts［J］. Mol Cancer Ther, 2018, 17(6):1207-1216.

［19］ Jin J, Fang H, Yang F, et al. Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer［J］. Neoplasia, 2018, 20(5):478-488.